在最新公布的临床数据中，歌礼制药旗下代谢性疾病候选药物Asc30展现出显著疗效。研究显示，受试者在接受为期三个月的每月一次给药方案后，至第16周时，经安慰剂校正的平均体重下降幅度达到7.5%。这一结果不仅凸显了该药物在体重管理领域的潜力，也为后续临床开发提供了重要依据。
在最新公布的临床数据中，歌礼制药旗下代谢性疾病候选药物Asc30展现出显著疗效。研究显示，受试者在接受为期三个月的每月一次给药方案后，至第16周时，经安慰剂校正的平均体重下降幅度达到7.5%。这一结果不仅凸显了该药物在体重管理领域的潜力，也为后续临床开发提供了重要依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.